Takeda secures FDA Priority Review for rusfertide NDA, potentially expediting a new treatment for polycythemia vera patients with a novel hepcidin-mimetic mechanism.

The FDA's Priority Review for rusfertide could expedite the availability of a new, non-cytoreductive treatment for polycythemia vera, a field with few recent therapeutic advancements. This signals a potential shift in the standard of care, moving beyond phlebotomy and existing drugs to a more targeted hepcidin-mimetic approach that addresses the underlying iron dysregulation.